MedTrace Logo

Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules

NCT02958696 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2017-02-03

No results posted yet for this study

Summary

HTL0018318 is a selective muscarinc M1 agonist. This study is a phase I, open label, randomised, crossover, single dose, trial in healthy volunteers to compare the relative bioavailability of HTL0018318 when given by oral aqueous solution and in capsule formulation.

Conditions

  • Bioavailability and Pharmacokinetics

Interventions

DRUG

HTL0018318

Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.

Sponsors & Collaborators

  • Nxera Pharma UK Limited

    lead INDUSTRY

Principal Investigators

  • Adeep Puri, MPhil MBBS · Hammersmith Medicines Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02958696 on ClinicalTrials.gov